Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 13/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3989236 | 0.97 | ALOX15 (0.94) | ALOX15KMT2AF2NPC1RAB9A | |
| SCHEMBL2909325 | 0.87 | ALOX15 (1.00) | ALOX15KMT2AF2NPC1ALDH1A1 | |
| SCHEMBL6003857 | 0.82 | ALOX15 (0.69) | ALOX15KMT2ANPC1RAB9AEPHX2 | |
| SCHEMBL6004365 | 0.76 | ALOX15 (0.61) | ALOX15KMT2AF2NPC1RAB9A | |
| SCHEMBL6003478 | 0.75 | ALOX15 (0.60) | ALOX15KMT2AEPHX2LMNA | |
| SCHEMBL6454874 | 0.73 | ALOX15 (0.57) | ALOX15LMNA | |
| SCHEMBL6002665 | 0.72 | ALOX15 (0.64) | ALOX15NPC1RAB9AALDH1A1EPHX2 | |
| SCHEMBL6004808 | 0.72 | ALOX15 (0.56) | ALOX15KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL5254653 | 0.71 | ALOX15 (0.55) | ALOX15NPC1RAB9ALMNA | |
| SCHEMBL5258097 | 0.68 | ALOX15 (0.51) | ALOX15NPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035573-B1 | METHODS FOR IDENTIFYING MODULATORS OF EOXIN FORMATION | BIOLIPOX AB (SE) | 2010-08-18 | — | — | EP | disclosed |
| US-20090247634-A1 | Methods for identifying modulators of eoxin formation | CLAESSON HANS-ERIK | 2009-10-01 | — | — | US | disclosed |
| US-20060183780-A1 | Pyrazole compounds useful in the treatment of inflammation | BIOLIPOX AB (SE) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247634-A1 | Methods for identifying modulators of eoxin formation | LTA4H, LTC4S, LTB4R2 | ALOX15 8/4885KMT2A 3941/4885PDK1 4371/4885 |
| US-20060183780-A1 | Pyrazole compounds useful in the treatment of inflammation | ALOX15, ALOX12, ALOX15B | ALOX15 1/4885KMT2A 4358/4885PDK1 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.